Sphera Funds Management LTD. purchased a new position in shares of AC Immune SA (NASDAQ:ACIU) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 503,563 shares of the company’s stock, valued at approximately $4,029,000.
Other institutional investors have also bought and sold shares of the company. State of New Jersey Common Pension Fund D bought a new position in AC Immune during the third quarter worth about $626,000. Compagnie Lombard Odier SCmA boosted its holdings in shares of AC Immune by 858.3% during the third quarter. Compagnie Lombard Odier SCmA now owns 33,539 shares of the company’s stock worth $268,000 after acquiring an additional 30,039 shares during the period. Artal Group S.A. boosted its holdings in shares of AC Immune by 25.0% during the third quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock worth $6,000,000 after acquiring an additional 150,000 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of AC Immune by 131.6% during the third quarter. Renaissance Technologies LLC now owns 52,300 shares of the company’s stock worth $418,000 after acquiring an additional 29,720 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in shares of AC Immune during the third quarter worth approximately $142,000. Institutional investors and hedge funds own 29.06% of the company’s stock.
Shares of NASDAQ:ACIU opened at $11.15 on Friday. AC Immune SA has a 12-month low of $7.16 and a 12-month high of $17.40. The company has a market cap of $702.10 million, a PE ratio of -37.17 and a beta of 1.27.
A number of equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded AC Immune from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Wednesday, November 21st. BidaskClub upgraded AC Immune from a “hold” rating to a “buy” rating in a report on Wednesday, November 21st. ValuEngine cut AC Immune from a “buy” rating to a “hold” rating in a report on Monday, August 20th. Finally, Leerink Swann assumed coverage on AC Immune in a report on Monday, November 12th. They set an “outperform” rating and a $18.00 price objective for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $15.25.
TRADEMARK VIOLATION NOTICE: This article was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.chaffeybreeze.com/2018/12/08/sphera-funds-management-ltd-invests-4-03-million-in-ac-immune-sa-aciu-stock.html.
AC Immune Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading: What are the economic characteristics of a bear market?
Want to see what other hedge funds are holding ACIU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AC Immune SA (NASDAQ:ACIU).
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.